Sygnature Discovery appoints Susanne Back as Head of In Vivo Pharmacology
She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River
She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River
The FDA approval makes PD-L1 IHC 22C3 pharmDx the only companion diagnostic approved to detect tumors expressing PD-L1 in esophageal or GEJ carcinoma patients for KEYTRUDA treatmen
Sugammadex injection is bioequivalent to Merck’s Bridion injection for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery
This strategic acquisition enables CORONA Remedies to penetrate deeper into targeted specialty and offer wider accessibility
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
The showcase, running March 27–31, puts a spotlight on everything from fine lines to daily sun protection
The CDMO Leadership Awards spotlight top-performing development and manufacturing service providers
The new assay consolidates screening for four major viral threats into a single workflow
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
Subscribe To Our Newsletter & Stay Updated